Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Gain Therapeutics (GANX) Return on Equity (2020 - 2025)

Gain Therapeutics (GANX) has 6 years of Return on Equity data on record, last reported at 4.04% in Q3 2025.

  • For Q3 2025, Return on Equity fell 194.0% year-over-year to 4.04%; the TTM value through Sep 2025 reached 4.04%, down 194.0%, while the annual FY2024 figure was 2.05%, 62.0% down from the prior year.
  • Return on Equity reached 4.04% in Q3 2025 per GANX's latest filing, down from 3.92% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.01% in Q4 2022 and bottomed at 4.04% in Q3 2025.
  • Average Return on Equity over 5 years is 1.3%, with a median of 0.36% recorded in 2023.
  • Peak YoY movement for Return on Equity: grew 16bps in 2022, then tumbled -225bps in 2023.
  • A 5-year view of Return on Equity shows it stood at 0.17% in 2021, then skyrocketed by 93bps to 0.01% in 2022, then tumbled by -18800bps to 2.27% in 2023, then dropped by -11bps to 2.51% in 2024, then crashed by -61bps to 4.04% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Equity were 4.04% in Q3 2025, 3.92% in Q2 2025, and 3.19% in Q1 2025.